Nichole Tucker

During the NCCN 2022 Annual Congress: Hematologic Malignancies, Aaron Gerds, MD, explained risk stratification in patients with polycythemia vera, frontline treatment options, and outcomes for the patient population based on findings from clinical trials.

In an interview with Targeted Oncology, Jeanny B. Aragon-Ching, discussed recent updates from the JAVELIN Bladder 100 trial. She also discussed ongoing research involving the novel agent EV-103 in patients with advanced or metastatic urothelial cancer.

The first of 160 patients with gastric or gastroesophageal junction cancer has been recruited for the phase 2 DisTinGuish study. Thirty-two study locations are actively recruiting more patients.

Considering the potential to fill a treatment gap in the KRAS G12C-mutant non–small cell lung cancer population, the FDA has granted a fast track designation to the combination of BBP-398 and sotorasib.

Data from the DREAMseq trial have answered a lingering question of how to sequence therapy for patients with advanced BRAF-mutant melanoma. This research supports immunotherapy in the first-line setting, followed by BRAK/MEK inhibitors.

In an interview with Targeted Oncology, Larisa Greenberg, MD discussed the current state of thyroid cancer, challenges, and where the field is headed in the near future.

Findings from the PERLA trial examining the combination of dostarlimab with pemetrexed followed by cisplatin or carboplatin will be presented at an upcoming medical conference. GSK hints that the combination improves objective response compared with pembrolizumab and chemotherapy.

Results from the phase 3 TRITON3 study show that rucaparib improves survival in multiple metastatic castration-resistant prostate cancer populations.

Building on data showing its preclinical anti-tumor activity, CUE-101 will be examined in a phase 1b study and has been granted FDA fast track designation.

Results from the phase 3 Study 302 of denileukin diftitoc in patients with persistent of recurrent cutaneous T-cell lymphoma led to the submission of a biologics license application for the drug.

In comparison with conventional transplant options, Orca-T may be more effective with a lower probability of infection in patients with hematologic malignancies.

Results from the POLARIX clinical trial support the use of polatuzumab vedotin plus rituximab as frontline treatment for diffuse large B-cell lymphoma.

During a debate a the SOHO 2022 Annual Meeting, Jennifer R Brown, MD, PhD presented in favor of combining small molecules in CLL. Making the argument for sequencing small molecules in CLL was Anthony Mato, MD.

Interim findings from the DREAMM-6 study hint that belantamab mafodotin plus lenalidomide and dexamethasone is effective with tolerable safety in patients with relapsed or refractory multiple myeloma.

The question of the most optimal therapy for Philadelphia chromosome-positive chronic myeloid leukemia has come down to asciminib vs ponatinib.

Results from the phase 3 AGILE study presented at SOHO 2022 show that ivosidenib plus azacitidine prolong event-free and overall survival with good responses vs placebo in patients with IDH1-mutated acute myeloid leukemia

During 10th Annual Meeting of the Society of Hematologic Oncology, Ajay Nooka, MD, discussed the new regimens with positive clinical trials in RRMM.

In the myeloma space, minimal residual disease negativity is prognostic of progression-free survival in relapsed or refractory patients. In leukemia, the biomarker combined with other prognostication techniques provides complex information that is clinically relevant.

In an interview with Targeted Oncology, Paul Richardson, MD, discussed the outcome of the ODAC meeting and provided his personal insights on what may be next for melphalan flufenamide.

A 5-year overall survival analysis led the FDA to question duvelisib for relapsed or refractory chronic lymphocytic leukemia. ODAC members voted that the benefit-risk profile of the drug is not favorable.

Based on the efficacy, toxicity, dose-optimization, and lack of confirmatory data for poziotinib in HER2 exon 20 insertion-positive non–small cell lung cancer, ODAC has voted that the drug has an unfavorable risk/benefit profile.

Following a report of impressive 2-year follow-up data, the FDA has granted a regular approval to selpercatinib.

With extended follow-up, selpercatinib has maintained its efficacy and safety in patients with RET fusion-positive non-small cell lung cancer.

In an interview with Targeted Oncology, Fred Saad, MD, FRSC, discussed key biomarkers for prostate cancer and findings from a biomarker analysis of the phase 3 PROpel clinical trial.

In season 3, episode 8 of Targeted Talks, Christie J. Hilton, DO, discusses treating first- and second-line HER2-positive breast cancer.

In an interview with Targeted Oncology™, Cyrus M. Khan, MD, discussed new strategies for the treatment of mantle cell lymphoma and needs for the future.

In the phase 3 CheckMate-76K study, adjuvant nivolumab administered to patients with stage IIB/C melanoma resulted in prolonged recurrence-free survival compared with placebo.

In patients with BRAF V600-mutated melanoma and central nervous system metastases, treatment with atezolizumab to vemurafenib plus cobimetinib achieved a good intracranial overall response rate. Responses were all achieved with the combination in patients with BRAF wild-type tumors.

Treatment with AST-301 will be explored in patients with HER2-low breast cancer in the phase 2 Cornerstone-011 study.

In an interview with Targeted Oncology, David Oubre, MD discussed the use of liquid biopsy to identify prognostic and predictive biomarkers in patients with non–small cell lung cancer. He also explained the results and implications of the INSIGHT study.